京新药业跌2.03%，成交额1.69亿元，主力资金净流出1116.79万元

Core Viewpoint - Jingxin Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 62.32%, despite a recent decline of 2.03% on September 8 [1]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion yuan, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 8, the stock price was 20.24 yuan per share, with a total market capitalization of 17.427 billion yuan [1]. - The stock has seen significant trading activity, with a turnover of 169 million yuan and a turnover rate of 1.14% on the same day [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 111 million yuan on July 4 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a slight decrease of 0.11% from the previous period [2]. - The average number of tradable shares per shareholder increased by 0.11% to 28,196 shares [2]. - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3].